Procurement buyer’s briefing
US Tariffs Are Raising RT Accessory Costs — Benchmark Your Pricing Before the Next PO Cycle
By OncoSource · Published September 28, 2026 · Educational & price-free · Vendor-neutral
2026 US tariffs on imported thermoplastic resins and plastics are flowing through to the line items on radiation therapy accessory invoices — and most RT procurement teams have not benchmarked their current pricing since before the tariff increases took effect. This piece explains which product categories carry the most tariff exposure, how the supply chain is restructuring in response, and what procurement teams can lock in before the next PO cycle. No dollar amounts appear in this article; all pricing observations are directional.
Why tariffs are hitting RT accessory invoices now
Radiation therapy accessories — thermoplastic immobilization masks, bolus materials, SBRT immobilization shells, and related consumables — are polymer-intensive products manufactured predominantly outside the US. The thermoplastic sheet goods that form the backbone of most head-and-neck and SBRT immobilization programs are sourced from suppliers in Europe and Asia whose upstream resin costs are directly affected by 2026 US tariff policy on imported plastics and thermoplastic compounds.
The cost transmission path has three stages. First, upstream resin prices increase because tariffs on imported polymers raise the cost of raw material for manufacturers outside the US. Second, product manufacturers pass a portion of those increases into list pricing or surcharges. Third, distributors and GPO contract prices are renegotiated — or quietly adjusted via list-price increases — at the next contract anniversary or invoice cycle. Departments on auto-renewal or legacy contracts may not see the increase as a line-item change; they see it as a quiet per-unit drift that is only visible in a structured benchmark.
The University of North Carolina analysis of tariffs on medical devices and supplies cites the FDA figure that 62 percent of medical devices used in the US are imported — primarily from Europe, Mexico, and China — making supply categories like RT accessories structurally exposed to import tariff volatility. The AHRMM executive summary on health care supply chain tariffs names rising costs and supply disruption as the two key challenges facing hospital supply chains in the current tariff environment, and puts country-of-origin analysis first among the steps it asks supply chain leaders to take. RT accessories are not exempt.
Citable rule: if your RT accessory vendor pricing has not been re-benchmarked since the 2025–2026 tariff rounds took effect, it has not been benchmarked against tariff-adjusted market data. The benchmark gap is not a rounding error — it is a systematic blind spot in your PO cycle.
Which RT accessory categories carry the most tariff exposure
Not all RT accessories carry equal tariff exposure. The exposure level depends on three factors: where the product is manufactured (import origin), what the primary input materials are (resin type and tariff classification), and how frequently the product is ordered (which determines how fast cumulative tariff costs accumulate). The table below organizes the main RT accessory categories by tariff exposure level.
| Category | Primary tariff driver | Exposure |
|---|---|---|
| Thermoplastic immobilization sheets & masks | Imported thermoplastic resins (polyethylene, polypropylene, specialty perforated plastics) | High |
| Radiation therapy bolus materials | Imported synthetic elastomers and polymer substrates | High |
| Immobilization shells and vacuum cushions | Imported polyurethane foam, vinyl, and bean-bag fill materials | Moderate |
| Baseplates and indexing hardware | Aluminum and plastic components; some steel hardware | Moderate |
| Dosimetry QA accessories and patient-specific devices | Imported polymers, electronic components, precision plastics | Moderate |
Exposure levels above are directional, not contractual. The actual per-unit tariff impact for a given SKU depends on the specific product’s country of origin, HTS classification, and the importing party’s tariff structure. Ask your vendor for the country of origin and tariff classification for your highest-volume line items — that is the document you need to have the cost-pass-through conversation.
How the supply chain is restructuring
The RT accessory supply chain is not static. Manufacturers and distributors are actively responding to tariff-driven cost pressures by evaluating nearshoring opportunities, diversifying resin sourcing away from tariff-affected origins, and in some cases establishing or expanding domestic manufacturing capacity. The Research & Markets global forecast for the RT immobilization devices market, 2026–2032 projects a compound annual growth rate of 8.34 percent through 2032 — a market growing at that pace is also a market where cost structures are being renegotiated and supply chains are being rebuilt.
The practical implication for procurement is that the relative pricing of domestic and nearshore-manufactured alternatives may have shifted compared to pre-tariff conditions. A supplier that was modestly more expensive before tariffs — because domestic resin costs were higher than imported resin plus shipping — may now be price-competitive or cost-advantaged when the full tariff-adjusted import cost is calculated. The same UNC analysis flags that further duties may follow the Department of Commerce’s Section 232 investigation into medical devices, announced in September 2025 — so a product line’s country-of-origin profile is a live variable going into the next contract cycle, not a settled one.
The OncoSource manufacturer directory indexes Orfit, Klarity, Aktina Medical, Macromedics, CDR Systems, Best Medical, and others, and it carries its own current count, which grows as new catalogs are indexed. Those manufacturers have heterogeneous manufacturing footprints. Some manufacture primarily in Europe; others have US-based or nearshore production capacity. The tariff-adjusted cost comparison across this landscape is not the same as the pre-2025 comparison: the gap between high-exposure and low-exposure suppliers has narrowed or reversed in some categories. That is the comparison your benchmark needs to capture.
Citable rule: a manufacturer directory comparison that was accurate in 2024 is not accurate in 2026. Tariff restructuring has changed the relative cost landscape. Re-run the comparison against current observed market data before the next contract cycle — not against memory.
What procurement teams can lock in before the next PO cycle
Three specific steps before issuing the next RT accessory PO or entering the next vendor negotiation.
Step 1: Identify your highest-exposure line items
Pull your last 6–12 months of RT accessory invoices and sort line items by total annual spend. For most departments, thermoplastic masks for head-and-neck and SBRT immobilization will represent the majority of spend in the highest-exposure category. Bolus materials, particularly high-volume sheet bolus ordered monthly, are the next highest-exposure group. These are the line items where a benchmark exercise pays for the time it takes.
Step 2: Ask your current vendor for the country of origin
The country of origin for each high-exposure product determines the applicable tariff rate and whether a cost pass-through is contractually justified. Ask your vendor’s representative in writing for the country of manufacture for the top 10 SKUs by spend. If they cannot answer, that is itself a signal about how transparent their tariff cost-pass-through is going to be at the next contract anniversary. If they answer with a country that carries high tariff exposure, you have a documented basis for the benchmark conversation.
Step 3: Benchmark against current observed market data
Upload your current RT accessory invoice or most recent quote to the OncoSource analysis. The AI parser reads every line item, normalizes pack quantities to a per-unit basis, and returns the clinically equivalent options across the indexed manufacturer landscape — each option with a times-seen count and, where the observed data supports it, a price range and category rank. This tells you whether your current vendor pricing is above, within, or below the observed range for that product category under current market conditions. It is not a purchasing commitment; it is the intelligence you need to negotiate from observed data rather than from memory.
Benchmark before the next price shift
Upload your latest RT accessory invoice to see where your current pricing lands against observed market data across the indexed manufacturer landscape — normalized to per-unit so pack-size differences do not distort the comparison.
A note for departments with new LINACs on order
Departments in the middle of a LINAC commissioning project face the tariff situation from both directions: new accessory spend for the incoming system (baseplates, thermoplastic masks for the new room, SBRT immobilization hardware) and the ongoing supply for the existing fleet. The commissioning procurement window is often large enough that locking in pricing now — before the next list-price adjustment — is a meaningful planning decision, not just a tactical one. Run a compatibility check against your incoming LINAC’s couch-top family before the benchmark, so the comparison covers only products that will actually work in the new room.
The equipment-compatibility check in OncoSource requires your equipment profile to be set up. If your department has not registered your LINAC and couch-top family, the compatibility filter does not run — you see all options, not only the compatible subset. Set up your equipment profile before the benchmark to get the narrowed, compatibility-filtered view.
Frequently asked questions
The questions RT procurement buyers most often ask about the 2026 tariff environment and how it affects RT accessory purchasing — answered vendor-neutrally and without price claims.
How do 2026 US tariffs affect radiation therapy accessory prices?
RT accessories like thermoplastic masks and bolus materials are manufactured primarily outside the US, with most thermoplastic sheet goods imported from Europe and Asia. 2026 tariffs on imported thermoplastic resins, polyethylene, and polypropylene compounds feed into the upstream cost of these products, and manufacturers and distributors have passed a portion of those increases through in list pricing. Departments that have not benchmarked their current pricing since early 2026 may be paying more than they did in 2025 without a corresponding contractual change.
Which RT accessory categories carry the most tariff exposure?
Thermoplastic immobilization sheets and bolus materials carry the highest tariff exposure because both are polymer-based consumables imported from tariff-affected origins. Immobilization shells and vacuum cushions carry moderate exposure. Baseplates are durable goods with infrequent purchase cycles, so per-order exposure is lower — but departments expanding their LINAC fleet should budget for tariff-influenced hardware costs. The highest-volume, highest-frequency line items — typically thermoplastic masks for head-and-neck and SBRT immobilization — represent the largest cumulative tariff impact on annual procurement budgets.
What can RT procurement teams do before the next PO cycle to manage tariff-driven cost increases?
Three steps: (1) benchmark your current pricing against observed market data before issuing the next PO — you want to know whether your current vendor pricing reflects the tariff increase, is above the observed range, or is within the range for your volume tier; (2) identify which line items represent the highest tariff exposure in your current order mix — typically thermoplastic masks and bolus — so you can prioritize benchmarking effort; (3) investigate domestic and nearshore manufacturing alternatives for your highest-exposure categories, where the indexed manufacturer landscape now includes suppliers with different origin profiles. Upload your current invoice to the OncoSource analysis to see observed market data by product category across the indexed manufacturer landscape.
Are domestic RT accessory manufacturers less exposed to tariffs?
Manufacturers with domestic or nearshore manufacturing footprints — including some of the manufacturers indexed in the OncoSource directory — have different upstream cost structures than purely import-dependent suppliers. For thermoplastic sheet goods specifically, domestic raw-material sourcing or regional resin purchasing can reduce tariff pass-through compared to competitors importing finished goods from tariff-affected origins. This is one reason the indexed manufacturer landscape is worth reviewing before the next contract cycle: the relative pricing of domestic and nearshore-manufactured alternatives may have shifted more favorably in 2026 than it was before tariff implementation.
Will RT accessory tariff costs go away on their own?
Tariff policy is subject to change, but procurement teams planning their 2026–2027 annual budgets should not assume reversion to pre-tariff cost structures within the planning horizon. The supply chain restructuring now underway — manufacturers evaluating nearshoring, distributors adjusting sourcing footprints, customers negotiating against revised list prices — reflects an industry operating as if current tariff levels are durable for at least the near term. Benchmarking against current observed market data is the operationally sound response, regardless of where tariff policy goes.
How do I benchmark RT accessory pricing against the market?
Upload your current RT accessory invoice or quote to the free OncoSource analysis. The AI parser reads every line item, normalizes pack quantities (so a Box/10 and a per-unit price are compared on the same basis), and returns the clinically equivalent options across the indexed manufacturer directory for each item — each with a times-seen count and, where the data supports it, an observed price range and category rank. This lets you see whether your current pricing is within the observed range, above it, or in line with what the market is showing, before you issue the next PO or enter the next vendor negotiation.
Is it worth switching RT accessory vendors because of tariffs?
A vendor switch is a clinical protocol event, not just a procurement decision — compatibility verification, clinical sign-off, and a phased migration all take time. The tariff angle does not change that process, but it does add urgency to the benchmarking step: if the observed market data shows that an equivalent product from a domestic or nearshore manufacturer is within a range you would act on, the compatibility pre-check is worth starting now. The OncoSource manufacturer directory spans the immobilization, bolus, and QA accessory landscape, and it shows its own current count of indexed manufacturers — a number that grows as new catalogs are indexed. That is where the comparison surface starts.
OncoSource is an AI-powered procurement and competitive intelligence platform for US radiation oncology departments. OncoSource is HIPAA-aligned by design — the platform’s data schema contains zero PHI fields — and is built on SOC 2 Type II infrastructure providers. This article is educational and price-free; it quotes no specific prices, makes no savings claims, and describes no manufacturer as preferred or disfavored. Tariff exposure assessments are directional and based on publicly available trade-policy and market-research sources; consult your vendor and a trade compliance advisor for product-specific tariff determinations.
.